Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab

RECOMMENDED

Multiple Sclerosis

Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing

Mult Scler Relat Disord.

Foley JF, Goelz S, Hoyt T, Christensen A, Metzger RR

doi: 10.1016/j.msard.

SPECIAL REPORT

Multiple Sclerosis

Vaccination Readiness in Multiple Sclerosis

Multiple Sclerosis

Monitoring CD49d Receptor Occupancy: A Method to Optimize and Personalize Natalizumab Therapy in Multiple Sclerosis patients

Cytometry B Clin Cytom.

Puñet-Ortiz J, Hervás-García JV, Teniente-Serra A, Cano-Orgaz A, Mansilla MJ, Quirant-Sánchez B, Navarro-Barriuso J, Fernández-Sanmartín MA, Presas-Rodríguez S, Ramo-Tello C, Martínez-Cáceres EM

doi: 10.1002/cyto.b.21527.

Multiple Sclerosis

Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies

Lancet Neurol.

Ho PR, Koendgen H, Campbell N, Haddock B, Richman S, Chang I

doi: 10.1016/

Multiple Sclerosis

Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients

J Neurol Sci.

Heesen C, Kleiter I, Meuth SG, Krämer J, Kasper J, Köpke S, Gaissmaier W

doi: 10.1016/j.jns.2017.03.001.

RECOMMENDED

Multiple Sclerosis

A review of the evidence for a natalizumab exit strategy for patients with multiple sclerosis

Autoimmun Rev.

Sellner J, Rommer PS

doi: 10.1016/j.autrev.2018.

SPECIAL REPORT

Multiple Sclerosis

Long-Term Real-World Use of Natalizumab Over 10 Years in Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis

Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients

Ann Neurol.

Dalla Costa G, Martinelli V, Moiola L, Sangalli F, Colombo B, Finardi A, Cinque P, Kolb EM, Haghikia A, Gold R, Furlan R, Comi G

doi: 10.1002/ana.25437.

Multiple Sclerosis

Natalizumab in Multiple Sclerosis: Long-Term Management

Int J Mol Sci.

Clerico M, Artusi CA, Liberto AD, Rolla S, Bardina V, Barbero P, Mercanti SF, Durelli L

doi: 10.3390/ijms18050940.

Related content

Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing

Vaccination Readiness in Multiple Sclerosis

Monitoring CD49d Receptor Occupancy: A Method to Optimize and Personalize Natalizumab Therapy in Multiple Sclerosis patients

Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies

Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients

A review of the evidence for a natalizumab exit strategy for patients with multiple sclerosis

Long-Term Real-World Use of Natalizumab Over 10 Years in Relapsing-Remitting Multiple Sclerosis

Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients

Natalizumab in Multiple Sclerosis: Long-Term Management